Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

797
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
797
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

628
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
628
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.6K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.6K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

367
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
367

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does Renal Sympathetic Denervation Impact the Outcome in Sepsis-Induced Shock? An Experimental Porcine Model.

Journal of clinical medicine·2026
Same author

Emerging evidence of neutrophil extracellular traps in essential hypertension and target organ damage: pathophysiological insights and therapeutic implications.

Hypertension research : official journal of the Japanese Society of Hypertension·2026
Same author

Beyond Single-Class Therapy: Real-World Combined Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.

Advances in therapy·2026
Same author

Computational intelligence using nailfold videocapillaroscopy for the prediction of carotid intima-media thickness in rheumatoid arthritis: a cohort-based study.

Rheumatology international·2026
Same author

Comparative Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Composite Surrogate Markers of Insulin Resistance: A Real-World Study Using METS-IR and SPISE.

Journal of clinical medicine·2026
Same author

Single Interventions (Pharmacological or Renal Denervation) Are Not Sufficient to Achieve Blood Pressure Control in Resistant Hypertension: A Systematic Review and Meta-Analysis.

Hypertension (Dallas, Tex. : 1979)·2026

Related Experiment Video

Updated: Apr 21, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.4K

PDE-5 inhibitors: clinical points.

Michael Doumas, Antonios Lazaridis, Niki Katsiki

  • 12nd Propedeutic Department of Internal Medicine, Hippokration Hospital, 49 Konstantinoupoleos street, 54643 Thessaloniki, Greece. michalisdoumas@yahoo.co.uk.

Current Drug Targets
|November 14, 2014
PubMed
Summary

Phosphodiesterase-5 inhibitors offer tailored erectile dysfunction treatment, revolutionizing sexual therapy. Careful consideration of cardiovascular effects and drug interactions, especially with nitrates and alpha-blockers, is crucial for safe and effective management.

More Related Videos

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.9K
Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
02:21

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Published on: March 15, 2024

2.1K

Related Experiment Videos

Last Updated: Apr 21, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.4K
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.9K
Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
02:21

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Published on: March 15, 2024

2.1K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Urology

Background:

  • Erectile dysfunction (ED) is often vascular and prevalent in men with cardiovascular disease (CVD).
  • Phosphodiesterase-5 (PDE5) inhibitors have transformed ED management.
  • PDE5 inhibitors have unique properties allowing personalized sexual therapy.

Purpose of the Study:

  • To review the evolution of sexual therapy for ED.
  • To detail the mechanism of action and characteristics of available PDE5 inhibitors.
  • To summarize PDE5 inhibitor efficacy, safety, and cardiovascular considerations.

Main Methods:

  • Literature review of PDE5 inhibitors in ED management.
  • Analysis of pharmacokinetic and pharmacodynamic properties.
  • Emphasis on cardiovascular safety and drug interactions.

Main Results:

  • PDE5 inhibitors demonstrate vasorelaxing and hemodynamic effects.
  • Co-administration with alpha-blockers requires caution; nitrates are contraindicated due to severe hypotension risk.
  • Individualized selection criteria for PDE5 inhibitors are discussed.

Conclusions:

  • PDE5 inhibitors provide effective ED treatment options.
  • Understanding drug interactions and cardiovascular implications is vital for patient safety.
  • Personalized therapy selection optimizes outcomes for men with ED and CVD.